Table 2.
Primary and secondary outcomes in patients with severe COVID-19 pneumonia receiving methylprednisolone (MP) alone, MP combined with tocilizumab, or usual care alone. One-way ANOVA test for all, Kruskal–Wallis test, and Fisher’s exact test/Chi-square test of proportionality were used. Results are presented as mean ± SD, unless otherwise indicated. ICU: intensive care unit.
| Variables | Control group (n = 27) | MP group (n = 23) | MP plus tocilizumab group (n = 26) | p-Values |
||
|---|---|---|---|---|---|---|
| Total (n = 76) | MP group versus control | MP plus tocilizumab versus control | ||||
| Length of hospital stay, days | 21 ± 19.85 | 20.83 ± 12.22 | 23.27 ± 8.96 | 0.800 | 0.9 | 0.5 |
| Admission to ICU | 9, 33.33% | 2, 8.69% | 6, 23.08% | 0.116 | 0.04 | 0.4 |
| Invasive mechanical ventilation | 9, 33.33% | 2, 8.69% | 6, 23.08% | 0.116 | 0.04 | 0.4 |
| Days on ventilators | 7.93 ± 14.86 | 1.09 ± 3.68 | 3.38 ± 7.11 | 0.052 | .03 | 0.1 |
| Length of ICU stay, days | 9.96 ± 16.73 | 2 ± 6.79 | 3.92 ± 7.99 | 0.043 | 0.03 | 0.1 |
| Day 45 mortality | 5, 18.5% | 1, 4.35% | 2, 7.69% | 0.231 | 0.129 | 0.2 |